Jones Financial Companies
CTKB icon

Jones Financial Companies’s Cytek Biosciences CTKB Stock Holding History

Jones Financial Companies’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.1K Hold
254
– – ﹤0.01% 4326
2025
Q4 		$1.28K Hold
254
– – ﹤0.01% 3959
2025
Q3 		$864 Hold
254
– – ﹤0.01% 3928
2025
Q2 		$902 Buy
+254
New +$846 ﹤0.01% 3680

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jones Financial Companies's CTKB Position: Q1 2026 in Review

Jones Financial Companies held its Cytek Biosciences (CTKB) position steady in Q1 2026 at 254 shares worth $1.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4326.

Jones Financial Companies first reported a position in CTKB in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.28K in Q4 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Jones Financial Companies held 254 shares of Cytek Biosciences worth $1.1K as of Q1 2026.
  • Jones Financial Companies left its Cytek Biosciences share count unchanged in Q1 2026.
  • Cytek Biosciences made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4326 holding.
  • Jones Financial Companies first reported a position in Cytek Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Jones Financial Companies's Cytek Biosciences position peaked at $1.28K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.